SGLT2 Inhibitors as Potential Anticancer Agents

Sodium-glucose cotransporter 2 (SGLT2) serves as a critical glucose transporter that has been reported to be overexpressed in cancer models, followed by increased uptake both mice and humans. Inhibition of its expression can robustly thwart tumor development vitro vivo. SGLT2 inhibitors are comparatively new class antidiabetic drugs have demonstrated anticancer effects several malignancies, including breast, liver, pancreatic, thyroid, prostate, lung cancers. This review aims assess the extent SGLT involvement different cell lines discuss pharmacology, mechanisms action, potential applications reduce tumorigenesis progression. Although these agents display common mechanism they exhibit distinct affinity towards type compared 1 varying extents bioavailability half-lives. While suppression attributed their primary mode mechanistic ways combat cancer, mitochondrial membrane instability, β-catenin, PI3K-Akt pathways, increase cycle arrest apoptosis, downregulation oxidative phosphorylation. Growing evidence ongoing clinical trials suggest benefit combination therapy using an inhibitor with standard chemotherapeutic regimen. Nevertheless, further experimental is required characterize role SGLTs types, activity subtypes,